PAMU
MRSN

Pictet Asset Management (UK)’s Mersana Therapeutics MRSN Stock Holding History

Pictet Asset Management (UK)’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$23.3M Buy
68,486
+330
+0.5% +$125K 0.03% 493
2021
Q1 		$27.6M Sell
68,156
-720
-1% -$349K 0.03% 441
2020
Q4 		$45.8M Buy
68,876
+13,582
+25% +$7.55M 0.06% 321
2020
Q3 		$25.7M Buy
55,294
+14,204
+35% +$7.18M 0.04% 387
2020
Q2 		$24M Buy
+41,090
New +$14M 0.04% 369

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Pictet Asset Management (UK)'s MRSN Position: Q2 2021 in Review

Pictet Asset Management (UK) increased its Mersana Therapeutics (MRSN) stake by 0.48% in Q2 2021, buying an estimated $125K and bringing the position to 68,486 shares worth $23.3M. The position accounts for 0.03% of the portfolio, ranked #493.

Pictet Asset Management (UK) first reported a position in MRSN in Q2 2020 and has held it in 5 quarters since. The position peaked at $45.8M in Q4 2020. 131 funds tracked by Wall St. Rank hold MRSN as of Q2 2021.

  • Pictet Asset Management (UK) held 68,486 shares of Mersana Therapeutics worth $23.3M as of Q2 2021.
  • Pictet Asset Management (UK) bought 330 Mersana Therapeutics shares in Q2 2021, an estimated $125K.
  • Mersana Therapeutics made up 0.03% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #493 holding.
  • Pictet Asset Management (UK) first reported a position in Mersana Therapeutics in Q2 2020 and has held it in 5 quarters since.
  • Pictet Asset Management (UK)'s Mersana Therapeutics position peaked at $45.8M in Q4 2020.
  • 131 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.